US › Healthcare

Minerva Neurosciences Inc (NERV)

US · Healthcare · Biotechnology

$2.35-2.89%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$17.5M

EPS

$-0.46

EPS estimate

$-0.01

EPS came in at -0.46 against a street estimate of -0.01 — a miss of 4500.0%.

Key statistics

Market cap

$112.2M

Forward P/E

11.2

P/B

2.68

Book value

$-4.52

EPS (TTM)

$-36.12

52-week high

$8.80

52-week low

$2.28

50-day MA

$3.91

200-day MA

$5.00

Beta

-0.12

Analyst view

Analysts rate Minerva Neurosciences Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $10.33.

Shareholding

Insiders

3.26%

Institutions

93.32%

Largest institutional holders

Fund	Stake
Federated Hermes Inc	9.78%
Jupiter Topco LLC	9.19%
Vivo Capital, LLC	9.05%
HHG PLC	8.99%
Balyasny Asset Management LLC	8.92%
Logos Global Management LP	6.89%
Farallon Capital Management, L.L.C.	4.95%
BlackRock Inc	4.69%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Minerva Neurosciences Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.